Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04864834




Registration number
NCT04864834
Ethics application status
Date submitted
15/04/2021
Date registered
29/04/2021
Date last updated
26/03/2024

Titles & IDs
Public title
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Scientific title
A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration
Secondary ID [1] 0 0
CSOK583A12301
Universal Trial Number (UTN)
Trial acronym
Mylight
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neovascular Age-related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - SOK583A1 (40 mg/mL)
Other interventions - Eylea EU (40 mg/mL)

Experimental: SOK583A1 (40 mg/mL) - Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

Active Comparator: Eylea EU (40 mg/mL) - IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
EU: European


Other interventions: SOK583A1 (40 mg/mL)
IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

Other interventions: Eylea EU (40 mg/mL)
IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.
Timepoint [1] 0 0
Change from baseline in mean BCVA score at Week 8
Secondary outcome [1] 0 0
Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU
Timepoint [1] 0 0
Week 1, 4, 8, 24 and 52
Secondary outcome [2] 0 0
Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU
Timepoint [2] 0 0
Week 8 and 52
Secondary outcome [3] 0 0
Similarity of Efficacy Between SOK583A1 and Eylea EU in Terms of BCVA
Timepoint [3] 0 0
Week 24 and 52
Secondary outcome [4] 0 0
Similarity Between SOK583A1 and Eylea EU in Terms of Safety
Timepoint [4] 0 0
52 weeks
Secondary outcome [5] 0 0
Similarity Between SOK583A1 and Eylea EU in Terms of Immunogenicity
Timepoint [5] 0 0
Week 52
Secondary outcome [6] 0 0
Systemic Exposure to SOK583A1 and Eylea EU in Participants of the Pharmacokinetic (PK) Assessment
Timepoint [6] 0 0
Baseline (pre-dose) and 24 hours after the first injection (day 2) and third injection (day 58)

Eligibility
Key inclusion criteria
Participants eligible for inclusion in this study must meet all of the following criteria:

1. Signed informed consent must be obtained prior to participation in the study

2. Participants must be 50 years of age or older at Screening

3. Anti-VEGF treatment-naive patients for either eye and systemically

4. Study eye diagnosed with active CNV lesions (type 1 and/ or type 2) secondary to AMD
and/or Retinal Angiomatous Proliferation lesions (type 3), affecting the central
subfield. Active CNV lesion is defined by the presence of leakage as evidenced by
fluorescein angiography, and intra- or subretinal fluid as evidenced by optical
coherence tomography, both confirmed by the CRC at Screening

5. Total area of CNV (including both classic and occult components) must comprise > 50%
of the total lesion area in the study eye, confirmed by the CRC at Screening

6. BCVA between 73 and 38 letters, both inclusive, in the study eye at Screening and
Baseline using ETDRS testing charts

7. Willing and able to comply with all study procedures, and be likely to complete the
study

8. Clear ocular media and adequate pupil dilatation in both eyes to permit good quality
photographic imaging.

Participants meeting any of the following criteria are not eligible for inclusion in this
study.

Ocular conditions and treatments:

1. Previous treatment with any anti-VEGF therapy in either eye or investigational drugs
in study eye or fellow eye, at any time prior to Baseline

2. Participant has received any approved treatment for nAMD (other than vitamin and
dietary supplements) in the study eye and at any time prior to Baseline

3. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of
-8 diopters or more negative), ocular histoplasmosis syndrome, angioid
streaks,choroidal rupture, or multifocal choroiditis in the study eye, assessed by
imaging at screening by CRC and appropriately stated in the multi-modal eligibility
confirmation report

4. Any active or suspected intraocular or periocular infection or suspected active
intraocular inflammation (e.g infectious conjunctivitis, keratitis, scleritis,
endophthalmitis, infectious blepharitis, uveitis) in either eye at Screening or
Baseline

5. Subfoveal fibrosis, atrophy, or scarring extending > 50% of total lesion area in the
study eye as assessed by the Investigator at Screening and confirmed by the CRC prior
to randomization

6. Subretinal hemorrhage that is = 50% of the total lesion area in the study eye, or if
the subretinal hemorrhage involving the fovea is 1 or more disc areas (= 2.54 mm2 ) in
size in the study eye, as assessed by Fluorescein Angiography (FA) and confirmed by
the CRC

7. Retinal pigment epithelium (RPE) rip/tear in the study eye at Screening or Baseline

8. Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within
4 weeks prior to Baseline

9. History or evidence of the following, in the study eye:

- Intraocular (including cataract surgery) or refractive surgery within the 90 day
period prior to Baseline. The yttrium aluminum garnet (YAG) posterior capsulotomy
is allowed no later than 4 weeks prior to Baseline

- Previous penetrating keratoplasty or vitrectomy

- Previous panretinal photocoagulation

- Previous photodynamic therapy

- Previous submacular surgery or other surgical intervention for AMD

- Retinal detachment or treatment or surgery for retinal detachment

- Any history of macular hole of stage 2 and above

- Prior trabeculectomy or other filtration surgery

- Ocular trauma within the 6-months period prior to Baseline

10. History of hypersensitivity to any of the study treatments or its excipients, or
clinically relevant sensitivity to fluorescein dye, as assessed by the Investigators

11. Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) > 25 mmHg
on medication or according to Investigator's judgment at Screening or Baseline

12. Aphakia and/or absence of the posterior capsule in the study eye at Screening or
Baseline, unless it occurred as a result of a YAG posterior capsulotomy in association
with prior posterior chamber intraocular lens implantation

13. Intra or periocular use of corticosteroids in the study eye within a 6 month period
prior to Baseline

14. Use of topical ocular corticosteroids in the study eye for 30 or more consecutive days
within the 90 days period prior to Baseline

15. Previous therapeutic radiation near the region of the study eye

16. Concomitant conditions or ocular disorders in the study eye, including media
opacities, cataract and diabetic macular edema, at Screening or Baseline which could,
in the opinion of the Investigator, prevent response to study treatment or may
confound interpretation of study results (efficacy and safety), compromise visual
acuity or require medical or surgical intervention during the course of the study

17. Presence of amblyopia, amaurosis or ocular disorders with BCVA <38 letters (ETDRS
testing charts) in the fellow eye at Screening (except when due to conditions whose
surgery may improve VA, e.g. cataract)

18. Presence of Scleromalacia in either eye

19. Participants requiring anti-VEGF treatment of the fellow eye at Baseline will not be
eligible for the PK substudy

Systemic conditions and treatments:

20. Previous systemic treatment with any anti-VEGF therapy

21. Use of systemic corticosteroids for 30 or more consecutive days within the 90 days
prior to Baseline, with the exception of low stable doses of corticosteroids (defined
as = 10 mg prednisolone or equivalent dose used for 90 days or more).

22. Uncontrolled blood pressure defined as a systolic value = 160 mmHg or diastolic value
= 100 mmHg at Screening

23. Stroke or myocardial infarction during the 6-month period prior to Baseline

24. Participation in an investigational systemic drug, biologic, or device study within 30
days or duration of 5 half-lives of the investigational product (whichever is longer)
prior to Baseline. Note: observational clinical studies solely involving
over-the-counter vitamins, supplements, or diets are not exclusionary

25. Presence of infection at screening or active infection within 2 weeks before screening

26. Underlying advanced, severe and uncontrolled concomitant condition (including, but not
limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine,
cardiac, inflammatory, infectious or gastrointestinal), physical examination finding,
or clinical laboratory finding which in the opinion of the Investigator place the
participant at unacceptable risk from participation in the study

27. History of a medical condition (including, but not limited to chronic disease
immunosuppression, metabolic dysfunction, prior exposure to other drugs that may pose
risk of infection or allergic reactions) that, in the judgment of the Investigator,
would preclude scheduled study visits, completion of the study, or a safe
administration of investigational product, or that might affect participant safety or
interpretation of the study results.

28. Pregnant or nursing (lactating) women and women of child-bearing potential, defined as
all women physiologically capable of becoming pregnant, unless they are using highly
effective methods of contraception while taking study treatment and for 3 months after
stopping the medication. Highly effective contraception methods include:

- Total abstinence (when this is in line with the preferred and usual lifestyle of
the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal,
post-ovulation methods) and withdrawal are not acceptable methods of
contraception.

- Female sterilization (have had surgical bilateral oophorectomy with or without
hysterectomy), total hysterectomy or tubal ligation at least six weeks before
taking investigational drug. In case of oophorectomy alone, only when the
reproductive status of the woman has been confirmed by follow up hormone level
assessment.

- Male sterilization (at least 6 months prior to screening). For female
participants on the study, the vasectomized male partner should be the sole
partner for that participant.

- Use of oral (estrogen and progesterone), injected or implanted hormonal methods
of contraception or other forms of hormonal contraception that have comparable
efficacy (failure rate <1%), for example hormone vaginal ring or transdermal
hormone contraception or placement of an intrauterine device (IUD) or
intrauterine system (IUS).
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/05/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/05/2023
Sample size
Target
Accrual to date
Final
485
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Sandoz Investigational Site - Albury
Recruitment hospital [2] 0 0
Sandoz Investigational Site - Liverpool
Recruitment hospital [3] 0 0
Sandoz Investigational Site - Parramatta
Recruitment hospital [4] 0 0
Sandoz Investigational Site - Sydney
Recruitment hospital [5] 0 0
Sandoz Investigational Site - Adelaide
Recruitment hospital [6] 0 0
Sandoz Investigational Site - Melbourne
Recruitment postcode(s) [1] 0 0
2640 - Albury
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2150 - Parramatta
Recruitment postcode(s) [4] 0 0
2000 - Sydney
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
3002 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
New Mexico
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
South Dakota
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Virginia
Country [13] 0 0
Austria
State/province [13] 0 0
Oberoesterreich
Country [14] 0 0
Austria
State/province [14] 0 0
Upper Austria
Country [15] 0 0
Austria
State/province [15] 0 0
Graz
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Sofia
Country [17] 0 0
Czechia
State/province [17] 0 0
Pardubice
Country [18] 0 0
Czechia
State/province [18] 0 0
Praha 5
Country [19] 0 0
Czechia
State/province [19] 0 0
Praha
Country [20] 0 0
France
State/province [20] 0 0
Bouches-Du-Rhone
Country [21] 0 0
France
State/province [21] 0 0
Indre Et Loire
Country [22] 0 0
France
State/province [22] 0 0
Paris
Country [23] 0 0
Germany
State/province [23] 0 0
Duesseldorf
Country [24] 0 0
Germany
State/province [24] 0 0
Frankfurt Am Main
Country [25] 0 0
Germany
State/province [25] 0 0
Freiburg
Country [26] 0 0
Germany
State/province [26] 0 0
Hannover
Country [27] 0 0
Germany
State/province [27] 0 0
Leipzig
Country [28] 0 0
Germany
State/province [28] 0 0
Mainz
Country [29] 0 0
Germany
State/province [29] 0 0
Marburg
Country [30] 0 0
Hungary
State/province [30] 0 0
HUN
Country [31] 0 0
Hungary
State/province [31] 0 0
Pest Megye
Country [32] 0 0
Hungary
State/province [32] 0 0
Budapest
Country [33] 0 0
Hungary
State/province [33] 0 0
Debrecen
Country [34] 0 0
Hungary
State/province [34] 0 0
Sopron
Country [35] 0 0
Hungary
State/province [35] 0 0
Szeged
Country [36] 0 0
Hungary
State/province [36] 0 0
Szekesfehervar
Country [37] 0 0
Israel
State/province [37] 0 0
Haifa
Country [38] 0 0
Israel
State/province [38] 0 0
Jerusalem
Country [39] 0 0
Israel
State/province [39] 0 0
Kfar Saba
Country [40] 0 0
Israel
State/province [40] 0 0
Lod
Country [41] 0 0
Israel
State/province [41] 0 0
Petach Tikva
Country [42] 0 0
Israel
State/province [42] 0 0
Rehovot
Country [43] 0 0
Israel
State/province [43] 0 0
Tel Aviv
Country [44] 0 0
Japan
State/province [44] 0 0
Aichi
Country [45] 0 0
Japan
State/province [45] 0 0
Fukuoka
Country [46] 0 0
Japan
State/province [46] 0 0
Hiroshima
Country [47] 0 0
Japan
State/province [47] 0 0
Hyogo
Country [48] 0 0
Japan
State/province [48] 0 0
Ibaraki
Country [49] 0 0
Japan
State/province [49] 0 0
Kagoshima
Country [50] 0 0
Japan
State/province [50] 0 0
Shizuoka
Country [51] 0 0
Japan
State/province [51] 0 0
Tokyo
Country [52] 0 0
Japan
State/province [52] 0 0
Yamaguchi
Country [53] 0 0
Latvia
State/province [53] 0 0
Riga
Country [54] 0 0
Lithuania
State/province [54] 0 0
Kauno Apskritis
Country [55] 0 0
Lithuania
State/province [55] 0 0
Vilnius
Country [56] 0 0
Poland
State/province [56] 0 0
Malopolska
Country [57] 0 0
Poland
State/province [57] 0 0
Bydgoszcz
Country [58] 0 0
Poland
State/province [58] 0 0
Lodz
Country [59] 0 0
Poland
State/province [59] 0 0
Lublin
Country [60] 0 0
Poland
State/province [60] 0 0
Wroclaw
Country [61] 0 0
Portugal
State/province [61] 0 0
Coimbra
Country [62] 0 0
Portugal
State/province [62] 0 0
Porto
Country [63] 0 0
Slovakia
State/province [63] 0 0
Slovak Republic
Country [64] 0 0
Slovakia
State/province [64] 0 0
Bratislava
Country [65] 0 0
Slovakia
State/province [65] 0 0
Trencin
Country [66] 0 0
Spain
State/province [66] 0 0
Asturias
Country [67] 0 0
Spain
State/province [67] 0 0
Catalunya
Country [68] 0 0
Spain
State/province [68] 0 0
Navarra
Country [69] 0 0
Spain
State/province [69] 0 0
Pais Vasco
Country [70] 0 0
Spain
State/province [70] 0 0
Barcelona
Country [71] 0 0
Spain
State/province [71] 0 0
Zaragoza

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sandoz
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1
and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.

The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU
in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive,
without important protocol deviations and adherent to the treatment and completed the
treatment to Week 8?
Trial website
https://clinicaltrials.gov/ct2/show/NCT04864834
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04864834